期刊文献+

用于治疗帕金森病的具神经保护潜能药物的研究进展及相关争议

下载PDF
导出
摘要 帕金森病是常见的以运动障碍为主要表现的神经退行性疾病,目前以多巴胺的替代治疗为主要治疗手段,但该疗法并不能延缓病程。长期以来,人们致力于寻找能延缓或阻止该病进展的神经保护药物,随着对帕金森病发病机制的不断深入研究,不少药物在动物实验和临床试验中均显示出有保护多巴胺能神经元的作用,但质疑和争议亦随之而来,迄今为止,尚无一种抗帕金森药被公认具有神经保护作用。该文就一些研究得最多同时也是争议最大的药物作出论述,对用于治疗帕金森病的神经保护药物的研发概况和各家见解作简单的介绍和总结。
出处 《新医学》 2009年第10期684-686,共3页 Journal of New Medicine
  • 相关文献

参考文献13

  • 1谢安木,刘焯霖,宁玉萍,王玉凯,李宝芹,刘平.Synphilin-1在帕金森病模型鼠脑内的表达[J].中山大学学报(医学科学版),2004,25(6):530-533. 被引量:3
  • 2MULLER T, HEFTER H, HUEBER R. Is levodopa toxic? [J] J Neurol, 2004, 251 (Suppl 6):Ⅵ/44- Ⅵ/46.
  • 3张凯娜.左旋多巴与乌灵胶囊治疗帕金森病伴发抑郁的临床研究[J].新医学,2005,36(3):154-156. 被引量:23
  • 4FAHN S, OAKES D, SHOULSON I. Levodopa and the progression of Parkinson's disease[J]. N Engl J Med, 2004, 351 (24) : 2498-2508.
  • 5IRAVANI M M, HADDON C O, COOPER J M, et al. Pramipexole protects against MPTP toxicity in non-human primates [J]. J Neurochem, 2006, 96 (5): 1315-1321.
  • 6MOLDZIO R, RADAD K, DUVIGNEAU J C, et al. Glutamate-induced cell death and formation of radicals can, be reduced by lisuride in mesencephalic primary cell culture[J]. J Neural Transm, 2006, 113 (9) : 1095- 1105.
  • 7PARKINSON STUDY GROUP. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease[J]. Arch Neurol, 2004, 61 (4) : 561-566.
  • 8ESPOSITO E, DI MATTEO V, BENIGNO A, et al. Non-steroidal anti-inflammatory drugs in Parkinson's disease[J]. Exp Neurol, 2007, 205 (2) : 295-312.
  • 9CHEN H, JACOBS E, SCHWARZSCHILD M A, et al. Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease[J]. Ann Neurol, 2005, 58 (6) : 963 -967.
  • 10HERNAN M A, LOGROSCINO G, GARCIA RODRIGUEZ L A, et al. Nonsteroidal anti-inflammatory drugs and the incidence of Parkinson disease[ J]. Neurology, 2006, 66 (7): 1097-1099.

二级参考文献22

  • 1王新德.帕金森病及帕金森综合征的诊断标准和鉴别诊断[J].中华神经精神科杂志,1985,18(4):256-256.
  • 2Slaughter JR, Slaughter KA. Prevalence, clinical manifestations, etiology,and treatment of depression in Parkinson's disease. J Neuropsychiaty Clin Neurosci, 2001, 13 (2): 187-188.
  • 3Kuopio AM, Marttila RJ. The quality of life in Parkinson's disease. Mov Disord, 2000, 15 (2): 216.
  • 4Leentjens AF, Verhey FR, lousberg R, et al. The validity of the hamilton and montgomery asberg depression rating scales as screening and dragnostic tools for depression in Parkinson's disease. Lnt J Ceriatr Psychiatry, 2000,15 (7), 644-649.
  • 5Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Ceriat Psychiatry, 1999, 14 (9): 711-713.
  • 6Johnson W G. Late-onset neurodegenerative diseases-the role of protein insolubility[J]. J Anat, 2000,196 (Pt 4):609-16.
  • 7Conway K A, Lee S J, Rochet J C, et al. Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson′ s disease: Implications for pathogenesis and therapy[J]. Biochemistry, 2000, (97): 571-6.
  • 8Kawamata H, McLean P J, Sharma N, et al. Interaction of alpha-synuclein and synphilin-1: effect of Parkinson′ s disease-associated mutations[J]. J Neurochem 2001, 77(3): 929-34.
  • 9Temsamani J, Guinot P. Antisense oligonucleotides:a new therapeutic approach[J]. Biotechnol Appl Biochem, 1997, 26 (3):65-71.
  • 10Agrawal S. Antisens oligonucleotides: towards clinical trials[J]. Trends Biotech, 1996, 14(10): 376-87.

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部